Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Mar-Apr 2015;49(2):215-23.
doi: 10.12740/PP/33911.

[GABAB Receptor as Therapeutic Target for Drug Addiction: From Baclofen to Positive Allosteric Modulators]

[Article in Polish]
Affiliations
Free article
Review

[GABAB Receptor as Therapeutic Target for Drug Addiction: From Baclofen to Positive Allosteric Modulators]

[Article in Polish]
Roberta Agabio et al. Psychiatr Pol. .
Free article

Abstract

The present paper summarizes experimental and clinical data indicating the therapeutic potential of the GABAB receptor agonist, baclofen, in the treatment of alcohol use disorder (AUD) and substance use disorder (SUD). Multiple preclinical studies have demonstrated the ability of baclofen to suppress alcohol drinking (including binge- and relapse-like drinking), oral alcohol self-administration, and intravenous self-administration of cocaine, nicotine, amphetamine, methamphetamine, morphine, and heroin in rodents. Some randomized, controlled trials (RCTs) and case reports support the efficacy of baclofen in suppressing alcohol consumption, craving for alcohol, and alcohol withdrawal symptomatology in alcohol-dependent patients. Data from RCTs and open studies investigating baclofen efficacy on SUD are currently less conclusive. Interest in testing high doses of baclofen in AUD and SUD treatment has recently emerged. Preclinical research has extended the anti-addictive properties of baclofen to positive allosteric modulators of the GABAB receptor (GABAB PAMs). In light of their more favourable side effect profile (compared to baclofen), GABAB PAMs may represent a major step forward in a GABAB receptor-based pharmacotherapy of AUD and SUD.

Keywords: Alcohol use disorder (AUD); GABAB receptor; Positive allosteric modulators.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources

Feedback